Antifungal Drugs Market: By Drug Class (Azoles, Polyenes, Echinocandins, Allylamines, Others), Route of Administration (Oral, Parenteral, Topical), Therapeutic Indications (Aspergillosis, Candidiasis, Dermatophytosis, Others), Distribution Channel (Retail pharmacies, Hospital pharmacies, Drug stores, Online pharmacies) and Geography

 

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Antifungal Drugs Market size is valued at USD 15,623.8 million in 2021 and is expected to grow at a CAGR of 3.9% during the forecast period 2022 to 2028. The global market provides a detailed overview and that can be segmented by drug type, by route of administration, by Therapeutic indication, and by distribution channel. By drug type, the Antifungal Drugs market growth has been segmented into Azoles, Polyenes, Echinocandins, Allylamines, and Others. The Azoles segment is likely to be the largest and fastest-growing segment in terms of drug type. Azoles are used to treat candidemia, blastomycosis, ocular fungal infections, and systemic candidiasis. It helps in fungistatic activities by hindering fungal enzymes. Azoles are also utilized in the treatment of systemic fungal infections, divided into imidazoles and triazoles. They provide an extensive spectrum of activity along with improved safety levels. Triazoles have less severe effects, fewer serious drug interactions, and enhanced distribution and absorption properties. The above-mentioned advantages of the use of azoles are attributed to the antifungal drug market share. Based on the Route of administration, the Antifungal Drugs market is segmented into Oral, Parenteral, and Topical. Among these, the Topical route of administration segment is expected to have a significantly growing market during the forecast period 2022-2028. Based on the Therapeutic indication, the Antifungal Drugs market is segmented into Aspergillosis, Candidiasis, Dermatophytosis, and Others. The Candidiasis segment is expected to have a significant share in 2021. Candidiasis is the most frequently happening systemic fungal infection. It is a yeast infection by the genus Candida. Its process to cure has changed over time. Some of the variations comprise suitable usage of broad-spectrum azoles and echinocandins for treatment of candidemia, invasive candidiasis, and mucosal candidiasis. Based on the distribution channel, the Antifungal Drugs market is segmented into Retail pharmacies, Hospital pharmacies, Drug stores, and Online pharmacies. Key Development: In June 2021, Mankind Pharma launched Posaconazole Gastro which was a tablet for drug resistance. In June 2021, Cadila Pharmaceuticals launched Posaconazole which can be used against an extensive range of fungal disorders.

Global Anti Fungal Drugs Market Summary

Study Period

2023-29

Base Year

2022

CAGR

3.9%

Largest Market

North America

Fastest Growing Market

Europe
Antifungal Drugs Market Dynamics

The growing incidences of nosocomial and fungal infections are anticipated to propel the market growth over the forecast years. Moreover, the growing healthcare expenditure, which helps in refining its infrastructure, is burgeoning the market growth over the forecast years.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Anti Fungal Drugs Market Segmentation

Drug Class
  • Azoles
  • Polyenes
  • Echinocandins
  • Allylamines
  • Others
Route of Administrat
  • Oral
  • Parenteral
  • Topical
Therapeutic Indicati
  • Aspergillosis
  • Candidiasis
  • Dermatophytosis
  • Others
Distribution Channel
  • Retail pharmacies
  • Hospital pharmacies
  • Drug stores
  • Online pharmacies

Frequently Asked Questions

According to CDC, in 2017, about 23,000 cases of invasive candidiasis were recorded.

The growth in the use of nanotechnology in the formulation of innovative antifungal drugs

The rise in the number of developing markets and the increasing number of drug launches and approvals.

The high price related to the antifungals and the growing population with antifungal drug resistance and the absence of healthcare infrastructure in developing countries.

1. Executive Summary 2. Global Anti fungal Drugs Market Introduction 2.1. Global Anti fungal Drugs Market – Taxonomy 2.2. Global Anti fungal Drugs Market –Definitions 2.2.1. Drug Class 2.2.2. Route of Administration 2.2.3. Therapeutic Indications 2.2.4. Distribution Channel 3. Global Anti fungal Drugs Market Dynamics 3.1. Drivers 3.2. Restraints 3.3. Opportunities/Unmet Needs of the Market 3.4. Trends 3.5. Global Anti fungal Drugs Market Dynamic Factors - Impact Analysis 3.6. Global Anti fungal Drugs Market – Competition Landscape 3.7. Epidemiology 4. Global Anti fungal Drugs Market Analysis,2013 - 2017 and Forecast, 2018 – 2024 4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) 4.3. Market OpportunityAnalysis 5. Global Anti fungal Drugs Market, By Drug Class, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 5.1. Azoles 5.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 5.1.3. Market Opportunity Analysis 5.2. Polyenes 5.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 5.2.3. Market Opportunity Analysis 5.3. Echinocandins 5.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 5.3.3. Market Opportunity Analysis 5.4. Allylamines 5.4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 5.4.3. Market Opportunity Analysis 5.5. Others 5.5.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 5.5.3. Market Opportunity Analysis 6. Global Anti fungal Drugs Market Forecast, By Route of Administration, 2013 - 2017 and Forecast, 2017 – 2024 6.1. Oral 6.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.1.3. Market Opportunity Analysis 6.2. Parenteral 6.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.2.3. Market Opportunity Analysis 6.3. Topical 6.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.3.3. Market Opportunity Analysis 7. Global Anti fungal Drugs Market Forecast, By Therapeutic Indications, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 7.1. Aspergillosis 7.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 7.1.3. Market Opportunity Analysis 7.2. Candidiasis 7.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 7.2.3. Market Opportunity Analysis 7.3. Dermatophytosis 7.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 7.3.3. Market Opportunity Analysis 7.4. Others 7.4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 7.4.3. Market Opportunity Analysis 8. Global Anti fungal Drugs Market Forecast, By Distribution Channel, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 8.1. Retail pharmacies 8.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 8.1.3. Market Opportunity Analysis 8.2. Hospital pharmacies 8.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 8.2.3. Market Opportunity Analysis 8.3. Drug stores 8.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 8.3.3. Market Opportunity Analysis 8.4. Online pharmacies 8.4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) Market Opportunity Analysis 9. Global Anti fungal Drugs Market Forecast, By Region, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 9.1. North America 9.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 9.1.3. Market Opportunity Analysis 9.2. Europe 9.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 9.2.3. Market Opportunity Analysis 9.3. Asia-Pacific 9.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 9.3.3. Market Opportunity Analysis 9.4. Latin America 9.4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 9.4.3. Market Opportunity Analysis 9.5. Middle East and Africa 9.5.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 9.5.3. Market Opportunity Analysis 9.6. Global Anti fungal Drugs Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024 10. North America Anti fungal Drugs MarketAnalysis,2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 10.1. Drug ClassAnalysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) 10.1.1. Azoles 10.1.2. Polyenes 10.1.3. Echinocandins 10.1.4. Allylamines 10.1.5. Others 10.2. Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 10.2.1. Oral 10.2.2. Parenteral 10.2.3. Topical 10.3. Therapeutic Indications Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 10.3.1. Aspergillosis 10.3.2. Candidiasis 10.3.3. Dermatophytosis 10.3.4. Others 10.4. Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 10.4.1. Retail pharmacies 10.4.2. Hospital pharmacies 10.4.3. Drug stores 10.4.4. Online pharmacies 10.5. Country Analysis 2016 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 10.5.1. U.S. 10.5.2. Canada 10.6. North America Anti fungal Drugs Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024 10.7. North America Anti fungal Drugs Market Dynamics – Trends 11. Europe Anti fungal Drugs Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 11.1. Drug Class Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) 11.1.1. Azoles 11.1.2. Polyenes 11.1.3. Echinocandins 11.1.4. Allylamines 11.1.5. Others 11.2. Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 11.2.1. Oral 11.2.2. Parenteral 11.2.3. Topical 11.3. Therapeutic Indications Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 11.3.1. Aspergillosis 11.3.2. Candidiasis 11.3.3. Dermatophytosis 11.3.4. Others 11.4. Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 11.4.1. Retail pharmacies 11.4.2. Hospital pharmacies 11.4.3. Drug stores 11.4.4. Online pharmacies 11.5. Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 11.5.1. Germany 11.5.2. UK 11.5.3. France 11.5.4. Spain 11.5.5. Italy 11.5.6. Russia 11.5.7. Poland 11.5.8. Rest of Europe 11.6. Europe Anti fungal Drugs Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024 11.7. Europe Anti fungal Drugs Market Dynamics – Trends 12. Asia-Pacific Anti fungal Drugs Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 12.1. Drug Class Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) 12.1.1. Azoles 12.1.2. Polyenes 12.1.3. Echinocandins 12.1.4. Allylamines 12.1.5. Others 12.2. Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 12.2.1. Oral 12.2.2. Parenteral 12.2.3. Topical 12.3. Therapeutic Indications Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 12.3.1. Aspergillosis 12.3.2. Candidiasis 12.3.3. Dermatophytosis 12.3.4. Others 12.4. Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 12.4.1. Retail pharmacies 12.4.2. Hospital pharmacies 12.4.3. Drug stores 12.4.4. Online pharmacies 12.5. Country Analysis2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 12.5.1. Japan 12.5.2. China 12.5.3. India 12.5.4. ASEAN 12.5.5. Australia & New Zealand 12.5.6. Rest of Asia-Pacific 12.6. Asia-Pacific Anti fungal Drugs Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024 12.7. Asia-Pacific Anti fungal Drugs Market Dynamics – Trends 13. Latin America Anti fungal Drugs Market Analysis, 2012 - 2012 - 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 13.1. Drug Class Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) 13.1.1. Azoles 13.1.2. Polyenes 13.1.3. Echinocandins 13.1.4. Allylamines 13.1.5. Others 13.2. Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 13.2.1. Oral 13.2.2. Parenteral 13.2.3. Topical 13.3. Therapeutic Indications Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 13.3.1. Aspergillosis 13.3.2. Candidiasis 13.3.3. Dermatophytosis 13.3.4. Others 13.4. Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 13.4.1. Retail pharmacies 13.4.2. Hospital pharmacies 13.4.3. Drug stores 13.4.4. Online pharmacies 13.5. Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 13.5.1. Brazil 13.5.2. Mexico 13.5.3. Argentina 13.5.4. Venezuela 13.5.5. Rest of Latin America 13.6. Latin America Anti fungal Drugs Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024 13.7. Latin America Anti fungal Drugs Market Dynamics – Trends 14. Middle East and Africa Anti fungal Drugs Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn) 14.1. Drug Class Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) 14.1.1. Azoles 14.1.2. Polyenes 14.1.3. Echinocandins 14.1.4. Allylamines 14.1.5. Others 14.2. Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 14.2.1. Oral 14.2.2. Parenteral 14.2.3. Topical 14.3. Therapeutic Indications Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 14.3.1. Aspergillosis 14.3.2. Candidiasis 14.3.3. Dermatophytosis 14.3.4. Others 14.4. Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 14.4.1. Retail pharmacies 14.4.2. Hospital pharmacies 14.4.3. Drug stores 14.4.4. Online pharmacies 14.5. Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 14.5.1. Gulf Cooperation Council (GCC) Countries 14.5.2. Israel 14.5.3. South Africa 14.5.4. Rest of MEA 14.6. MEA Anti fungal Drugs Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024 14.7. MEA Anti fungal Drugs Market Dynamics – Trends 15. Competition Landscape 15.1. Strategic Dashboard of Top Market Players 15.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis) 15.2.1. Pfizer, Inc. (U.S.) 15.2.2. Novartis AG (Switzerland) 15.2.3. Sanofi (France) 15.2.4. Merck & Co., Inc. (U.S.) 15.2.5. Enzon Pharmaceuticals, Inc. (U.S.) 15.2.6. Bayer AG (Germany) 15.2.7. Astellas Pharma, Inc. (Japan) 15.2.8. GlaxoSmithKline plc. (U.K.) 15.2.9. Mylan N.V. (U.S.), Tecan Group (Switzerland) 15.2.10. AureoGen Biosciences Inc. (U.S.) 16. Research Methodology 17. Key Assumptions and Acronyms
  • Pfizer, Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Merck & Co., Inc. (U.S.)
  • Enzon Pharmaceuticals, Inc. (U.S.)
  • Bayer AG (Germany)
  • Astellas Pharma, Inc. (Japan)
  • GlaxoSmithKline plc. (U.K.)
  • Mylan N.V. (U.S.)
  • Tecan Group (Switzerland)
  • AureoGen Biosciences Inc. (U.S.)